Company shares are trading at $6.19 which is just a bit higher than the 50 day moving average of $5.87 and which is marginally higher than the 200 day moving average of $6.17. The 50 day moving average moved up $0.32 whereas the 200 day average was up by +0.40%. 168K shares changed hands in the last trading session. Overall, volume was down 49.19% under the stocks normal daily volume.
Traders are a little more bearish on shares of Aratana Therapeutics, Inc. of late as inferred by the change in short interest. The firm had a rise in short interest of 11.74% as of the latest report on August 31, 2017. Short interest grew 384,761 over that period. With short interest at 3,662,877 and short average daily volume at 291,390, days to cover is 13.0 and the short interest percentage is 0.09% as of August 31.
Aratana Therapeutics, Inc. (NASDAQ:PETX) has been the object of insider selling activity recently. Ernst Heinen, Chief Development Officer disclosed the sale of 10,000 shares. The shares were purchased at an average price of $6.25. Heinen now owns $818,713 of the stock per the Form 4 SEC filing.
The following firms have recently changed their position in PETX. As of quarter end Janus Capital Management LLC had disposed of a total of 2,353 shares trimming its stake by 0.2%. The value in dollars decreased from $10,245,000 to $7,550,000 decreasing 26.3% quarter over quarter. As of the end of the quarter Baird Financial Group, Inc. had bought 3,655 shares growing its holdings by 9.0%. The value of the investment in PETX went from $216,000 to $321,000 a change of $105,000 since the last quarter.
As of the end of the quarter Trexquant Investment Lp had bought 1,773 shares growing its position 6.0%. The value of the company’s investment in Aratana Therapeutics, Inc. went from $188,000 to $228,000 a change of 21.3% quarter to quarter. Ubs Group Ag divested its ownership by selling 698 shares a decrease of 29.6%. Ubs Group Ag owns 1,662 shares with a value of $12,000. The value of the position overall is down by 7.7%.
In the latest earnings report the EPS was $-1.61 and is projected to be $-1.09 for the current year with 43,001,000 shares currently outstanding. Next quarter’s EPS is estimated at $-0.24 with next year’s EPS anticipated to be $-0.44.
Aratana Therapeutics, Inc., launched on December 1, 2010, is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Business’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Business’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Business’s product candidates also include AT-014 for dogs..